Background. Sleep apnea (SA) is common and has prognostic significance among broad groups of patients with heart failure (HF). There are no data characterizing the presence, associations, and prognostic significance of SA among persons living with human immunodeficiency virus (PLHIV) with HF.
The life expectancy of persons living with HIV (PLHIV) on antiretroviral therapy (ART) has increased and has resulted in HIV being considered a chronic disease [1] [2] [3] [4] [5] [6] . In this context, PLHIV are facing a heightened risk of age-related comorbidities including heart failure (HF). Indeed, the risk of incident HF is increased more than 2-fold among PLHIV on ART [1, 3, 6] . There are 2 types of HF: HF with a preserved ejection fraction and HF with a reduced EF (HFrEF). Compared to uninfected controls with HF, PLHIV with both types of HF have worse cardiovascular outcomes [3, 7] . The mechanisms underlying the increased occurrence of adverse outcomes among PLHIV with HF remain unclear. Sleep apnea (SA) is particularly common among broad groups of patients with HFrEF and is associated with increased morbidity and mortality in that population [8] [9] [10] . Among PLHIV without known HF, sleep disturbances are reported in up to 70% [11, 12] . Therefore, as SA is a cause of increased morbidity and mortality among uninfected patients with HFrEF, outcomes among PLHIV with HF are poor, and SA may be common among PLHIV, we aimed to test the presence, characteristics, associations, and prognostic significance of SA among PLHIV with HFrEF.
Our aim in this study was to add to the limited knowledge about SA in PLHIV with HF. We hypothesized that SA was highly prevalent among PLHIV with HFrEF and that the presence of SA among PLHIV with HFrEF was associated with worse outcomes.
METHODS

Study Design and Patient Population
After obtaining institutional board review approval, we retrospectively analyzed data on the 2578 patients admitted to a US tertiary care hospital (Bronx-Lebanon Hospital Center of Mount Sinai School of Medicine, Bronx, New York) in 2011 with a primary diagnosis of acute decompensated HF. Individuals who had left ventricular ejection fraction (LVEF) ≥50% (n = 1088), recent (≤ 3 months) history of myocardial infarction (n = 65), cardiac surgery (n = 72), coronary revascularization (n = 141), acute myocarditis, or pericarditis (n = 88) were excluded from the study. The final study group of 1124 individuals hospitalized with HFrEF consisted of 172 PLHIV and 952 uninfected controls. The diagnoses of HIV, HF, and SA were ascertained through manual review of each individual's electronic health record (EHR). An HF admission was defined per the American College of Cardiology and American Heart Association key data elements and definitions for cardiovascular endpoint events. An HF admission was defined as a hospital admission with a primary diagnosis of HF and length of stay of at least 24 hours, with new or worsening symptoms of HF on presentation, objective evidence of new or worsening HF, and initiation or intensification of treatment specifically for HF [13] . SA was diagnosed with polysomnography with an apnea-hypopnea index of ≥5 along with oxygen desaturation during sleep.
Outcomes
Our primary outcome was 30-day HF hospital readmission rate, defined according to European Society of Cardiology consensus criteria [14] and ascertained through physician-adjudicated individual EHR review. The follow-up period began on the date of discharge from the first HF hospitalization in 2011. Our secondary outcomes included rates of cardiovascular (CV) mortality and all-cause mortality. CV death was defined as death due to HF, sudden cardiac death, arrhythmias, or acute ischemic events [15] . Death was determined through the Social Security death index and confirmed by physician-adjudicated individual EHR review.
Covariates
Through EHR review, data were collected on traditional HF risk factors (including hypertension, dyslipidemia, diabetes mellitus, coronary artery disease [CAD] , family history of CAD, body mass index [BMI] , prior or active cigarette smoking, and prior or active cocaine use) as well as on presence, characteristics, and severity of SA; type of SA (central vs obstructive); apnea-hypopnea index (AHI); continuous positive airway pressure (CPAP) use; and daily duration of CPAP use [7, 16, 17] . Also through EHR review, data were collected on medication use at the time of discharge from the index HF hospitalization. Details on HIVspecific parameters (current ART, duration of ART, CD4 count, viral load [VL]) were recorded from those available closest to the time of discharge from the index HF hospitalization.
Statistical Analyses
Continuous variables are presented as mean and standard deviation or median (interquartile range [IQR]), as appropriate, based on normality, and categorical variables are presented as percentages. Continuous data were compared using unpaired Student t tests or Wilcoxon rank-sum tests, as appropriate. Categorical data were compared using the χ 2 or Fisher exact test. Comparisons were made between the following groups: PLHIV with and without SA, HIV-uninfected controls with and without SA, PLHIV with SA and HIV-uninfected controls without SA, and PLHIV with SA with central sleep apnea (CSA) vs PLHIV with SA with obstructive sleep apnea (OSA). Survival curves were plotted using Kaplan-Meier curves. Univariate and multivariate regression analyses were performed to determine the association between baseline covariates and 30-day HF hospital readmission rate. Multivariate Cox proportional hazard regression analyses for the 30-day HF hospital readmission rate were constructed using a P value < .01 on the univariate analysis for entry. Otherwise, statistical significance was defined using a 2-tailed P value ≤ .05. Both VL and CD4 count were not included in the multivariate model together due to the overlap between those individuals with a low CD4 count and a high VL. Similarly, both CPAP use and CPAP duration were not included in the multivariate model together. PLHIV admitted with HFrEF who also had SA were further divided based on median AHI, the use of CPAP, and median nightly duration of CPAP. Statistical analyses were performed using SPSS software version 24.
RESULTS
Demographics and Baseline Characteristics
Among PLHIV with HFrEF, 92% (159/172) were on ART (median duration, 8.5 years; IQR, 4-16 years). In this group, the mean CD4 count was 293 cells/mm 3 and the median VL was 279 copies/mL (range, <50 to 3 000 457). Fifty-three percent (91/172) had a CD4 count ≥200 cell/mm 3 , 37% (64/172) had a VL <50 copies/mL, and 60% (102/172) had VL <200 copies/mL. SA was noted in 28% of PLHIV (48/172) with HFrEF and 26% (248/952) of uninfected controls with HFrEF ( Figure 1 ). The prevalence of SA was similar between PLHIV with HFrEF and uninfected controls with HFrEF ( Table 1) . Comparison of PLHIV with HFrEF with and without SA revealed that PLHIV with HFrEF and SA had a higher pulmonary artery systolic pressure (PASP) and BMI. However, HIVspecific parameters (CD4 count, VL, and ART use) were similar between these 2 groups. Comparison of HIV-uninfected controls with HFrEF with and without SA revealed that HIV-uninfected controls with HFrEF and SA had a higher LVEF, higher BMI, and lower percentage of spironolactone use (Table 1) . When patients with HFrEF and SA with and without HIV were compared, those individuals with HIV had a lower BMI and LVEF, a higher PASP, were more likely to have OSA rather than CSA, and were more likely to use CPAP for a longer duration (Table 1) . Finally, within the group of patients with HIV, HFrEF, and SA, those with CSA were compared to those with OSA: PLHIV with CSA had higher rates of hypertension (80% vs 60%), a lower BMI (29 ± 5.0 vs 34 ± 4.5 kg/m 2 ), a lower LVEF (27 ± 6.8 vs 39 ± 4.5%), a higher PASP (57 ± 7.3 vs 46 ± 8 .3 mm Hg), and more severe SA (AHI, 36 vs 15/hour) compared to those with OSA (Table 2) . Additionally, PLHIV with HFrEF and CSA had a lower CD4 count (117 vs 389 cells/mm 3 ) and lower rates of viral suppression (13% vs 51%,) compared to PLHIV with HFrEF and OSA ( Table 2) .
Outcomes
Among the entire cohort, 55% were re-admitted with decompensated HF within 30 days of discharge from the incident HF hospitalization. Among PLHIV with HFrEF, factors associated with an increased 30-day HF hospital readmission rate on univariate analysis included traditional HF risk factors (diabetes mellitus, a history of CAD, increased PASP), the use of traditional medications for HFrEF (beta blocker, angiotensin converting enzyme inhibitor/angiotensin receptor blocker), nontraditional HF risk factors (cocaine use), HIV-specific parameters (low CD4 count and high VL), and parameters relating to SA (AHI, CPAP use duration) (Supplementary Table 1 ). In multivariable modeling conducted among PLHIV with HFrEF, the following parameters remained independently associated with increased 30-day HF readmission rate among PLHIV with HFrEF: history of CAD, increased PASP, cocaine use, low CD4 count (or high VL), and high AHI. CPAP use and duration of CPAP use were associated with a lower 30-day HF hospital readmission rate in this group (Table 3 and Supplementary Tables 2 and 3 ).
The median AHI was 24/hour among the PLHIV who were diagnosed with SA. The 30-day HF hospital readmission rate was compared between those above and below the median AHI. The 30-day hospital readmission rate was higher in PLHIV with HFrEF with an AHI ≥24/hour vs AHI <24/hour (84% vs 13%, P < .001; Figure 2) . In a univariable model, the following factors were associated with an increased AHI among PLHIV with SA: a history of CAD, smoking, higher VL, lower CD4 count, lower LVEF, and higher PASP (Supplementary Table 4) . In a multivariable model, smoking, CD4 count (or VL), and PASP were independently associated with an increased AHI (Supplementary Table 5 ). The 30-day HF hospital readmission rate was also compared between those who were and were not using CPAP. The 30-day HF hospital readmission rate was markedly increased among PLHIV with SA who were not using CPAP (100% vs 40%, P < .001; Figure 3) . Finally, the 30-day HF hospital readmission rate was compared between those using CPAP with a duration of use of ≤4 hours per day compared to >4 hours per day. The longer duration of CPAP use among PLHIV with HFrEF was associated with a lower 30-day HF hospital readmission rate (27% vs 63%, P = .03; Figure 4 ).
Among PLHIV, CV and all-cause mortality rates were increased among PLHIV with HFrEF with an elevated AHI (CV mortality, 56% vs 13%, P = .002; all-cause mortality, 72% vs 22%, P < .001; Figure 2 ), among those who were not using CPAP (CV mortality, 50 vs 24%; all-cause mortality, 70% vs 39%; Figure 3) , and among those with a shorter median duration of CPAP use (CV mortality, 42% vs 20%; all-cause mortality, 58% vs 33%; Figure 4 ).
DISCUSSION
Here, we aimed to assess how SA influences outcomes among PLHIV with HFrEF. While the presence of SA among PLHIV with HFrEF was similar to that in uninfected controls, there were notable differences.
When patients with HFrEF and SA with and without HIV were compared, those individuals with HIV were more likely to have OSA rather than CSA and were more likely to use CPAP for a longer duration. Among patients with HFrEF and SA, those individuals with HIV also had a lower BMI as well as a lower LVEF and a higher PASP. When PLHIV with SA were divided according to the type of SA, central vs obstructive, those with CSA had a lower BMI, a lower LVEF, a higher PASP, and an increased AHI compared to those with OSA. Additionally, PLHIV with HFrEF with CSA had a lower mean CD4 count and lower rates of viral suppression. Significant predictors of 30-day HF hospital readmission among PLHIV with HFrEF included not only traditional HF risk factors (CAD, PASP), nontraditional HF risk factors (cocaine use), and HIV-specific parameters (low CD4 count or high VL) but also factors related to SA. Indeed, SA severity was positively associated with 30-day HF hospital readmission rate. Each 1-hour increase in CPAP use was associated with a 14% decreased risk of 30-day HF hospital 
The bold values mean statistically significant difference. readmission. Similar findings of an effect of SA severity (AHI) and CPAP use and duration of CPAP were noted for CV and all-cause mortality.
The prevalence of SA was similar between HFrEF patients with SA noted in 28% of PLHIV with HFrEF compared to 26% of uninfected controls. There are no prior data detailing the prevalence of SA among PLHIV with HFrEF. However, there are data on the presence of SA among uninfected controls with HFrEF. These data show a range in prevalence of SA among patients with HF from 4% to 70% depending on whether routine sleep testing was performed [18] [19] [20] [21] [22] . However, the type of SA differed, and studies note a difference in the type of SA according to the presence or absence of HF [23] . Specifically, there are 3 types of SA: OSA, CSA, and mixed [23, 24] . Among patients without HF, OSA is the most common, and, among patients with HF, CSA is rare [8, 25] . However, studies among broad groups of individuals with HF show markedly increased rates of CSA [26] . For example, in a prospective study of 700 The bold values mean statistically significant difference.
patients with HFrEF, Oldenburg et al noted CSA in 53% of HFrEF with SA [18] . We had similar findings among our HIVuninfected control group with SA, with CSA noted in 45%. However, among PLHIV with HFrEF and SA, rates of CSA were lower and rates of OSA were higher in comparison to uninfected controls. CSA usually occurs because of transient reduction by the pontomedullary pacemaker while the breathing rhythm is being generated I response to the changes in the partial pressures of carbon dioxide that can fall below the apnea threshold. In contrast, OSA is defined by upper airway occlusion yielding reduced airflow as a result of upper airway edema, tongue falling posteriorly, and, most importantly, obesity [8] . In PLHIV, rates of OSA compared to CSA may be increased due to several factors. Primarily, ART may lead to lipodystrophy and fat deposition in areas including the neck, causing obstruction, as well as in the thorax and abdomen, decreasing end-expiratory lung volume [27] [28] [29] .
This finding has prognostic importance. Among patients with HF without known HIV, CSA has been shown to be an independent risk marker for poor prognosis and death [30] [31] [32] , and CSA in HF is associated with a worse outcome than OSA. The finding of a difference in the type of SA may also have therapeutic relevance. Specifically, despite concerns about compliance, we found that almost 80% of our HIV population with HF were using CPAP and that the median duration of nightly CPAP use was greater among PLHIV. In a multivariable model, both CPAP use and duration of CPAP use were independent predictors of HF rehospitalization. Findings of a beneficial effect of CPAP uses on broad cardiovascular outcomes have previously been demonstrated. For example, in a study involving 720 patients [33] , the use of CPAP was associated with a lower risk of atrial fibrillation, with a greater benefit seen in those with longer duration of CPAP use. Similarly, in a study of 725 patients with SA, the use of CPAP for less than 4 hours per night was associated with an increase in CV events [34] . The effect of CPAP on outcomes among individuals with HF appears less consistent, but the variability is likely related to the type of HF. For example, in a prospective study involving 60 patients with HFrEF, Blanco et al showed that CPAP treatment improved the LVEF in patients with OSA by 9%; however, no significant improvement was noted in individuals with CSA [24] . In comparison, in adaptive servo-ventilation therapy to treat central sleep apnea in systolic HF patients, adaptive servo ventilation therapy among a HFrEF cohort with CSA was associated with an increase in overall mortality [35, 36] . When data from PLHIV with HFrEF with CSA and OSA were compared, PLHIV with HFrEF and SA with CSA had a higher AHI and prevalence of hypertension, lower BMI, lower LVEF, higher PASP, lower CD4 count, and higher VL.
The limitations to our study include its retrospective nature based on a single US urban tertiary care center. Therefore, these data may not be generalizable, and prospective studies of outcomes associated with HFrEF hospitalizations among large, diverse populations of individuals with HIV with SA are needed.
In conclusion, we are the first to report on the presence, associations, and prognostic implications of SA among PLHIV with HFrEF. Compared to uninfected controls with HFrEF and SA, PLHIV are more likely to have OSA rather than CSA. Apnea severity is associated with adverse HF outcomes, whereas CPAP use and increased duration of CPAP use conferred protection. Moreover, cocaine use, low CD4 count, and high VL were associated with the increased rate of 30-day HF readmission among PLHIV. Additional research on strategies that may improve outcomes among PLHIV hospitalized with HFrEF along with other outcomes that influence comorbidities is needed. 
